We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Taste-Based Influenza Test Could Replace Nasal Swabs with Chewing Gum

By LabMedica International staff writers
Posted on 07 Oct 2025

Influenza is one of the most dangerous infectious diseases worldwide, claiming around half a million lives each year. More...

What makes it particularly insidious is that flu viruses are contagious even before the first symptoms appear. Yet, diagnostic options are often expensive, complicated to use, and unavailable in many poorer regions. Now, a new, very simple self-test in the form of chewing gum or a lollipop could detect infection within minutes by producing a recognizable taste when an active virus is present.

This rapid test, developed by researchers at the University of Würzburg (Würzburg, Germany), is based on a diagnostic principle that combines a sensor molecule (thymol, a natural flavor carrier) with a virus-specific recognition component so that active influenza viruses trigger release of the flavor in saliva. The method is flexible: flavor carrier and recognition component can be swapped (sweet, bitter, or salty flavors and alternative pathogen-specific building blocks), and the group envisions delivery formats such as chewing gum or lollipops that require no laboratory, electricity, or medical personnel.

In an experimental study, clinical samples were collected and documented by hospital teams while investigations on influenza virus particles were carried out in partner labs to validate the sensor concept. The proof-of-concept work, published in ACS Central Science, shows that contact between active influenza viruses and the neuraminidase-specific sensor releases the flavoring molecule, producing a clearly recognizable taste in infected mouths but not in uninfected controls. as.

The researchers are now working on incorporating the sensors into chewing gum or lollipops and adapting the system for mass production, a process they estimate will take about four years. They believe such low-threshold diagnostics would be particularly suitable for critical locations such as schools, nurseries, and retirement homes, and could be crucial in poorer countries for outbreak control. In the longer term, they envisage voluntary reporting via a smartphone app to map spread in real time and the use of artificial intelligence (AI) to predict where epidemics or pandemics might develop.

“Instead of relying on expensive and complicated testing procedures, we use the natural human sensory system – taste – as a tool for the early detection of infections,” said Professor Lorenz Meinel, who led the study. “This strategy opens up new possibilities for the early detection and control of influenza worldwide.”

Related Links:
University of Würzburg


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.